A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Public ClinicalTrials.gov record NCT00850993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
It is a normal process in the human body for red blood cells to die, which makes bilirubin. Bilirubin is cleared away through the liver. Some babies are born with livers that don't work well enough yet, or their red blood cells are dying too fast, so the baby looks yellow (jaundice). This means there is too much bilirubin in the body. It can be dangerous if a baby's bilirubin gets too high. Phototherapy is what they call the lights they shine on newborn babies to help the liver get rid of bilirubin. This study tests an experimental drug to see if it can reduce how much bilirubin is being made in the first place.
Study identification
- NCT ID
- NCT00850993
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Minute to 48 Hours
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2008
- Primary completion
- May 31, 2011
- Completion
- Apr 30, 2012
- Last update posted
- Oct 29, 2019
2008 – 2012
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arrowhead Regional Med Center | Colton | California | 92324 | — |
| UCSD Medical Center | San Diego | California | 92103 | — |
| Kapi'olani Medical Center for Women and Children | Honolulu | Hawaii | 96826 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| ECU Brody School of Medicine | Greenville | North Carolina | 27834 | — |
| St. Vincent Mercy Children's Hospital | Toledo | Ohio | 43608 | — |
| Drexel University College of Medicine, Clinical Research Group | Philadelphia | Pennsylvania | 19102 | — |
| Albert Einstein Medical Center | Philadelphia | Pennsylvania | 19141 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00850993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2019 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00850993 live on ClinicalTrials.gov.